Androgens
Norethandrolone
A steroid with a randomized maintenance-treatment study in older adults with acute myeloid leukemia; that narrow context matters.
Randomized phase III open-label oncology trial; evidence checked 2026-10-01
Practical use
Evidence interpretation and concrete review questions
- Preserve the full regimen context
- Include induction, remission status and maintenance treatment.
- Name the endpoint
- Do not substitute disease-free survival for overall survival.
- Check current oncology relevance
- A published trial does not alone establish today’s preferred care for an individual.
Overview
Norethandrolone is an anabolic androgen studied as part of a complete leukemia-treatment pathway. The GOELAMS trial tested its addition to maintenance care after induction and reinduction therapy, not steroid treatment alone.
Risks and limitations
The trial reported no increase in toxicity under its oncology setting. That does not establish general safety in healthy users, other diseases or unmonitored exposure; serious cancer care has a different benefit–risk context.
How to read this
This is a genuine clinical outcome study, but its favorable result must remain attached to the disease, prior treatment and time-dependent analysis.
Research explained
GOELAMS maintenance study
Who was studied
330 patients aged at least 60 with acute myeloid leukemia randomized equally to a norethandrolone-containing or control maintenance strategy.
What was found
Five-year overall survival was 26.3% versus 17.2%; disease-free survival was 31.2% versus 16.2%. The modeled benefit emerged among patients still in remission one year after induction.
What it cannot establish
Open-label, disease-specific combined treatment with a time-dependent effect. It cannot establish benefit for other cancer regimens or nonmedical use.
Read the original studyMaintenance is part of a longer pathway
The study cannot be summarized as steroids curing leukemia; patients also received intensive cancer treatment.
Supporting sourceTiming changes interpretation
The reported benefit was not a uniform immediate effect from the start of therapy.
Supporting sourceClaims versus findings
Incorrect extrapolation
A survival benefit in leukemia validates general anabolic use.
The studied disease and treatment context are essential to the result.
Check the evidenceCommon questions
Is overall survival the same as disease-free survival?
No. The study reported them separately, with different numerical results.
SourceSources
PubChem chemical identity; checked October 1, 2026
Sources checked 2026-10-01.
General education; not a personal treatment plan.